Patents by Inventor Ana Belen Bueno Melendo

Ana Belen Bueno Melendo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUNDS
    Publication number: 20230373927
    Abstract: In an embodiment, the present invention provides a compound of the formula: wherein R1 is selected from the group consisting of F and H; R2 is selected from the group consisting of CH3, CH3CHCH3 and —NHCH2CH(CH3)2; R3 is selected from the group consisting of H and —CH2OCH3; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H and CH3; R6 is selected from the group consisting of H and OH; R7 is selected from the group consisting of or a pharmaceutically acceptable salt thereof, and methods of using this compound for positive allosteric modulation of a receptor selected from the group consisting of GLP1, GIP, and glucagon.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 23, 2023
    Inventors: Ana Belén BUENO MELENDO, Jayana Pankajkumar LINESWALA, Gema RUANO PLAZA, Nuria Diaz BUEZO
  • GPR119 agonists
    Patent number: 8207344
    Abstract: GPR119 agonist compounds of the formula: and pharmaceutical compositions for the treatment of diabetes and obesity.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: June 26, 2012
    Assignee: Eli Lilly and Company
    Inventors: David Gene Barrett, Ana Belen Bueno Melendo, Jeffry Bernard Franciskovich, Bin Liu, Kumiko Takeuchi
  • Compounds and methods for modulating FXR
    Patent number: 8153624
    Abstract: Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Michael James Genin, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Alan M. Warshawsky
  • Cyclopropyl compounds
    Patent number: 8063079
    Abstract: A compound of the formula: and pharmaceutical compositions for the treatment of diabetes.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: November 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Ana Belen Bueno Melendo, Francisco Javier Agejas-Chicharro
  • GPR119 Agonists
    Publication number: 20110015199
    Abstract: GPR119 agonist compounds of the formula: and pharmaceutical compositions for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 12, 2010
    Publication date: January 20, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: David Gene Barrett, Ana Belen Bueno Melendo, Jeffry Bernard Franciskovich, Bin Liu, Kumiko Takeuchi
  • Compounds and methods for modulating FX-receptors
    Patent number: 7863302
    Abstract: Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: January 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors
    Patent number: 7745438
    Abstract: The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.
    Type: Grant
    Filed: September 20, 2005
    Date of Patent: June 29, 2010
    Assignee: Eli Lilly and Company
    Inventors: Howard Barff Broughton, Robert Dean Dally, Timothy Barrett Durham, Maria Rosario Gonzalez-Garcia, Patric James Hahn, Kenneth James Henry, Jr., Todd Jonathan Kohn, James Ray McCarthy, Timothy Alan Shepherd, Jon Andre Erickson, Ana Belen Bueno Melendo
  • CYCLOPROPYL COMPOUNDS
    Publication number: 20100160395
    Abstract: A compound of the formula: and pharmaceutical compositions for the treatment of diabetes.
    Type: Application
    Filed: December 11, 2009
    Publication date: June 24, 2010
    Inventors: Ana Belen Bueno Melendo, Francisco Javier Agejas-Chicharro
  • COMPOUNDS AND METHODS FOR MODULATING FXR
    Publication number: 20100152166
    Abstract: Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.
    Type: Application
    Filed: July 11, 2008
    Publication date: June 17, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Michael James Genin, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Alan M. Warshawsky
  • Amides as BACE inhibitors
    Patent number: 7618978
    Abstract: The present invention provides BACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: November 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: Ana Belen Bueno Melendo, Shu-Hui Chen, Maria Rosario Gonzalez-Garcia, James Ray McCarthy
  • Compounds and Methods for Modulating Fx-Receptors
    Publication number: 20080306125
    Abstract: Compounds of formula. wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.
    Type: Application
    Filed: February 2, 2007
    Publication date: December 11, 2008
    Inventors: Michael Gregory Bell, Michael James Genin, Peter Ambrose Lander, Lindsay Scott Stelzer, Robert Anthony Doti, Francisco Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Peter Rudolph Manninen, Jason Matthew Ochoada, Quanrong Shen, Alan M. Warshawsky, Tianwei Ma, Ryan Edward Stites
  • Isochroman compounds for treatment of CNS disorders
    Patent number: 7335660
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: February 26, 2008
    Assignee: Eli Lilly and Company
    Inventors: Javier Agejas-Chicharro, Graham Henry Timms, Andrew Caerwyn Williams, Nicholas Paul Camp, Jeremy Gilmore, Ana Belen Bueno Melendo, Carlos Lamas-Peteira
  • Prodrugs of excitatory amino acids
    Patent number: 7038077
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: May 2, 2006
    Assignee: Eli Lilly and Company
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Prodrugs of excitatory amino acids
    Publication number: 20040248963
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residues R11, R12 and R13 are as defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.
    Type: Application
    Filed: April 30, 2004
    Publication date: December 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Mark Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Matthew John Valli
  • Prodrugs of excitatory amino acids
    Publication number: 20040176459
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: December 10, 2003
    Publication date: September 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Rafael Ferritto Crespo, Marc Francis Herin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Matthew John Valli
  • Prodrugs of excitatory amino acids
    Publication number: 20040138304
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 15, 2004
    Inventors: Anne Hollins Dantzig, James Allen Monn, Stephanie Ann Sweetana, Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Marc Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Carlos Montero Salgado, Concepcion Pedregal-Tercero
  • Pharmaceutical compounds
    Publication number: 20040122001
    Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.
    Type: Application
    Filed: January 16, 2004
    Publication date: June 24, 2004
    Inventors: Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Nicholas Paul Camp, Jeremy Gilmore, Alma Maria Jimenez-Aguado, Carlos Lamas-Peteira, Alicia Marcos-Llorente, Michael Philip Mazanetz, Carlos Montero Salgado, Graham Henry Timms, Andrew Caerwyn Williams
  • Excitatory amino acid receptor modulators
    Patent number: 6498180
    Abstract: Compounds of formula (I) in which R1 is halo-C1-10 alkyl; halo-C2-10 alkenyl; or (CH2)nY in which n is 1 or 2 and Y is OH, CN, N3, OR3, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-tetrazol-5-yl, 5-phenyltetrazol-2-yl or PO3H2; R3, R5, R6, R7, R8 and R9 are each selected independently from C1-4 alkyl, aryl and aryl-C1-4 alkyl; R4 is selected from C1-4 alkyl, aryl, aryl-C1-4 alkyl, and 1H-tetrazol-5-yl, carboxy-(1-4C)alkyl and 1H-tetrazol-5-yl-C1-4 alkyl; and p is 0, 1, 2 or 3; or a salt or ester thereof, provided that R1 is not methoxymethyl, modulate metabotropic glutamate receptor function and are useful in treating disorders of the central nervous system.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: December 24, 2002
    Assignee: Eli Lilly and Company
    Inventors: Ivan Collado Cano, Concepcion Pedregal Tercero, Alicia Marcos Llorente, Beatriz Lopez de Uralde Garmendia, Maria Rosario Gonzalez Garcia, Ana Belen Bueno Melendo